Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002736 (
amyotrophic lateral sclerosis
)
19,048
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mutations in the gene progranulin (PGRN) were recently identified as the cause of some forms of frontotemporal dementia with ubiquitin-positive intraneuronal inclusion pathology (FTLD-U). The DNA-binding protein,
TDP-43
, was determined to be a component of these ubiquitinated inclusions in FTLD-U and
amyotrophic lateral sclerosis
(
ALS
) with dementia (
ALS
-D). These findings raise many interesting questions as to the shared pathology and possible common pathologic process between
ALS
and FTLD-U. This study examines the immunoexpression of PGRN in
ALS
patients using immunohistochemical analysis of post-mortem tissue. Available brain and spinal cord sections of eight
ALS
patients, including one case with severe dementia, and eighteen control-aged brains were stained with anti-PGRN antibodies. We found increased staining for PGRN in motor tracts with vacuolar degeneration and glial cells in
ALS
sample spinal cord and brainstem sections compared to controls. Variable upper motor neuron staining and reactive glia were seen in
ALS
motor cortex samples. Frontal lobe and hippocampal sections showed no consistent differences from control tissues with the exception of the
ALS
-dementia case, which showed PGRN immunoexpression in non-motor cortical areas. These results describe a pattern of increased PGRN expression in areas of active degeneration in
ALS
. The meaning of this association is unclear, but may indicate a potential role for PGRN in the variable expression of motor and cognitive deficits in the
ALS
-FTD spectrum.
...
PMID:Progranulin (PGRN) expression in ALS: an immunohistochemical study. 1884 8
Recently, sporadic
amyotrophic lateral sclerosis
(SALS), a fatal neurological disease, has been shown to be a multisystem proteinopathy of
TDP-43
in which both neurons and glial cells in the central nervous system are widely affected. In general, the natural history of SALS is short (<5 years). However, it is also known that a few patients may survive for 10 years or more, even without artificial respiratory support (ARS). In the present study using
TDP-43
immunohistochemistry, we examined various regions of the nervous system in six patients with SALS of long duration (10-20 years) without ARS, in whom lower motor-predominant disease with Bunina bodies and ubiquitinated inclusions (UIs) in the affected lower motor neurons was confirmed. One case also showed UIs in the hippocampal dentate granule cells (UDG). In all cases, except one with UDG, the occurrence of
TDP-43
-immunoreactive (ir) neuronal cytoplasmic inclusions (NCIs) was confined to a few regions in the spinal cord and brainstem, including the anterior horns. In one case with UDG,
TDP-43
-ir NCIs were also detected in the substantia nigra, and some regions of the cerebrum, including the hippocampal dentate gyrus (granule cells). The number of neurons displaying NCIs in each region was very small (1-3 per region, except the dentate gyrus). On the other hand, the occurrence of
TDP-43
-ir glial cytoplasmic inclusions (GCIs) was more widespread in the central nervous system, including the cerebral white matter. Again, however, the number of glial cells displaying GCIs in each region was very small (1-3 per region). In conclusion, compared to the usual form of SALS,
TDP-43
pathology shown in SALS of long duration was apparently mild in degree and limited in distribution, corresponding to the relatively benign clinical courses observed. It is now apparent that SALS of long duration is actually part of a
TDP-43
proteinopathy spectrum.
...
PMID:Sporadic amyotrophic lateral sclerosis of long duration is associated with relatively mild TDP-43 pathology. 1892 36
TDP-43
(also known as TARDBP) regulates different processes of gene expression, including transcription and splicing, through RNA and DNA binding. Moreover, recent reports have shown that the protein interacts with the 3'UTRs of specific mRNAs. The aberrant cellular distribution and aggregation of
TDP-43
were recently reported in neurodegenerative diseases, namely frontotemporal lobar degeneration (FTLD) and
amyotrophic lateral sclerosis
(
ALS
). A detailed description of the determinants for cellular localization has yet to emerge, including information on how the known functions of
TDP-43
and cellular targeting affect each other. We provide the first experimental evidence that
TDP-43
continuously shuttles between nucleus and cytoplasm in a transcription-dependent manner. Furthermore, we investigate the role of the functional
TDP-43
domains in determining cellular targeting through a combination of immunofluorescence and biochemical fractionation methods. Our analyses indicate that the C-terminus is essential for solubility and cellular localization, because its deletion results in the formation of large nuclear and cytoplasmic aggregates. Disruption of the RNA-recognition domain required for RNA and DNA binding, however, alters nuclear distribution by decreasing
TDP-43
presence in the nucleoplasm. Our findings suggest that
TDP-43
solubility and localization are particularly sensitive to disruptions that extend beyond the newly found nuclear localization signal and depend on a combination of factors that are closely connected to the functional properties of this protein.
...
PMID:Structural determinants of the cellular localization and shuttling of TDP-43. 1895 8
There is mounting pathological, biochemical and genetic evidence that the metabolism and aggregation of the 43-kDa transactive response (TAR)-DNA-binding protein (
TDP-43
) play a crucial role in the pathogenesis of sporadic and some forms of familial
amyotrophic lateral sclerosis
(
ALS
). Recently, it was reported using an ELISA system that elevated levels of
TDP-43
were detected in plasma samples from patients with Alzheimer's disease and frontotemporal dementia, compared to healthy controls. To determine whether quantification of
TDP-43
in cerebrospinal fluid (CSF) is potentially informative in the diagnosis of
ALS
, we measured the concentration, by a similar ELISA method, of
TDP-43
in CSF from 30 patients with
ALS
(diagnosed according to the revised El Escorial criteria) and 29 age-matched control patients without any neurodegenerative disease. We found that, as a group, the
ALS
patients had significantly higher levels of
TDP-43
in their CSF than the age-matched controls (6.92 +/- 3.71 ng/ml in
ALS
versus 5.31 +/- 0.94 ng/ml in controls, p < 0.05), with levels of
TDP-43
in CSF elevated beyond 95% upper confidence level for the control group in six (20%) of the patients with sporadic
ALS
. All the six patients with higher levels of CSF
TDP-43
were examined within 10 months of the onset of illness. The patients examined within 10 months of onset showed significantly higher levels of CSF
TDP-43
(8.24 +/- 4.72 ng/ml) than those examined after 11 months or more of onset (5.41 +/- 0.66 ng/ml, p < 0.05). These results suggest that the levels of
TDP-43
in CSF may increase in the early stage of
ALS
. We also confirmed the existence of the
TDP-43
protein in CSF from some patients with
ALS
, and a control subject, by western blotting of proteins immunocaptured from the CSF samples. Raised
TDP-43
levels in the CSF may preempt the formation of
TDP-43
pathology in the central nervous system, or correlate with early-stage
TDP-43
pathology, and accordingly be a biomarker for the early stage of
ALS
.
...
PMID:Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. 1898 84
Wobbler mice model motor neuron disease with a substantial decline in motor neurons.
TDP-43
is a nucleic acid binding protein that accumulates, along with ubiquitin, in the cytoplasm of
amyotrophic lateral sclerosis
(
ALS
) motor neurons. Recently, it was reported that Cu/Zn superoxide dismutase type 1 (SOD1) familial
amyotrophic lateral sclerosis
(fALS) model mice do not mimic the
TDP-43
changes seen in sporadic
ALS
, although they share a large number of other properties with the human disorder. We examined ubiquitin inclusions and
TDP-43
expression in wobbler mice.
TDP-43
mRNA, measured by quantitative reverse transcription-coupled PCR, was elevated in the wobbler spinal cord. Immunohistochemistry revealed intracellular ubiquitin inclusions and abnormal distribution of
TDP-43
into the cytoplasm in wobblers similar to the staining reported in
ALS
. Finally, nuclear and cytoplasmic fractions, examined by Western immunoblotting, confirmed a delocalization of
TDP-43
in the neurodegenerative wobbler. These observations indicate that wobbler mice, which suffer motor neuron loss at 21 days, undergo
TDP-43
and ubiquitin changes characteristic of sporadic
ALS
.
...
PMID:Wobbler mice modeling motor neuron disease display elevated transactive response DNA binding protein. 1901 2
We have performed sciatic axotomies in adult C57BL/6 mice and observed
TDP-43
and progranulin (PGRN) expression patterns over 28 days.
TDP-43
expression was markedly upregulated in axotomized motor neurons, with prominent cytosolic immunoreactivity becoming maximal by post-injury day 7 and returning to baseline levels by post-injury day 28. Increased
TDP-43
expression was confirmed by western blot.
TDP-43
mRNA expression was also increased. This was inversely correlated with neuronal PGRN expression which was clearly reduced by day 7 with a return to baseline by post-injury day 28. In contrast, microglial PGRN expression was dramatically increased, and correlated with the inflammatory response to axotomy. Cytosolic
TDP-43
colocalized with Staufen and TIA-1, markers for RNA transport and stress granules respectively. We did not observe colocalization of
TDP-43
or PGRN with degradative granules (P-bodies) or activated caspase 3. These results indicate that
TDP-43
expression is altered in response to neuronal injury and that normal expression is restored following recovery. These findings suggest that the upregulation of
TDP-43
expression with prominent cytosolic localization in motor neurons injured by degenerative processes such as
ALS
may actually represent an appropriate response to neuronal injury.
...
PMID:Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. 1904 46
There is an ongoing discussion whether
ALS
is primarily a disease of upper motor neurons or lower motor neurons. We undertook a review to assess how new insights have contributed to solve this controversy. For this purpose we selected relevant publications from 1995 onwards focussing on (1) primary targets and disease progression in
ALS
and variants of
ALS
, (2) brain imaging markers for upper motor neuron lesion, and (3) evidence for
ALS
being a multisystem disorder. Clinically, upper motor and lower motor neuron symptoms can occur in any order over time. Brain imaging markers show upper motor neuron involvement in early disease. Overlap syndromes of
ALS
and dementia, and involvement of autonomic and sensory nerves occur frequently. PET/SPECT scans, functional MRI and voxel based morphometry studies clearly show abnormalities in extra-motor areas of the brain. Pathologically, the 43 kDa TAR DNA-binding protein (
TDP-43
) provides a clue to these overlapping disorders. In conclusion, evidence accumulates that
ALS
is a multisystem disorder rather than a pure lower and/or upper motor neuron disorder.
...
PMID:Upper motor neuron and extra-motor neuron involvement in amyotrophic lateral sclerosis: a clinical and brain imaging review. 1907 Apr 91
TAR DNA binding protein
43 (TDP-43) has been considered a signature protein in frontotemporal dementia and
amyotrophic lateral sclerosis
(
ALS
), but not in
ALS
associated with the superoxide dismutase 1 (SOD1) gene mutations (ALS1). To clarify how TDP may be involved in
ALS
pathogenesis, clinical and pathological features in cases of sporadic
ALS
([SALS] n = 18) and ALS1 (n = 6) were analyzed. In SALS patients with rapid clinical courses, TDP mislocalization (i.e. cytoplasmic staining and TDP-positive cytoplasmic inclusions) in anterior horn cells was frequent. In SALS patients with slow clinical courses, TDP-43 mislocalization was rare. In an ALS1 patient with the SOD1 gene mutation C111Y, there were numerous TDP-positive inclusions and colocalization of SOD1 and TDP. In mutant SOD1 transgenic (G93A) mice at the end stage (median, 256 days), TDP-positive inclusions and TDP colocalization with SOD1 were also observed; nuclear TDP-43 immunoreactivity was highly correlated with life span in these mice. In both humans and mice, nuclei that stained strongly for TDP were large and circular; weakly stained nuclei were atrophic or deformed. In conclusion, low levels of TDP expression in the nucleus cor relate with a rapid clinical course in SALS and in ALS1 model mice, suggesting that nuclear TDP may play a protective role against motor neuron death resulting from different underlying etiologies.
...
PMID:Nuclear TAR DNA binding protein 43 expression in spinal cord neurons correlates with the clinical course in amyotrophic lateral sclerosis. 1910 47
We report phosphorylated and ubiquitinated aggregates of
TAR DNA binding protein
of 43 kDa (TDP-43) in SH-SY5Y cells similar to those in brains of
amyotrophic lateral sclerosis
(
ALS
) and frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U). Two candidate sequences for the nuclear localization signal were examined. Deletion of residues 78-84 resulted in cytoplasmic localization of TDP-43, whereas the mutant lacking residues 187-192 localized in nuclei, forming unique dot-like structures. Proteasome inhibition caused these to assemble into phosphorylated and ubiquitinated TDP-43 aggregates. The deletion mutants lacked the exon skipping activity of cystic fibrosis transmembrane conductance regulator (CFTR) exon 9. Our results suggest that intracellular localization of TDP-43 and proteasomal function may be involved in inclusion formation and neurodegeneration in TDP-43 proteinopathies.
...
PMID:Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells. 1911 50
TDP-43
(43-kDa TAR DNA-binding domain protein) is a major constituent of ubiquitin-positive cytoplasmic aggregates present in neurons of patients with fronto-temporal lobular dementia and
amyotrophic lateral sclerosis
(
ALS
). The pathologic significance of
TDP-43
aggregation is not known; however, dominant mutations in
TDP-43
cause a subset of
ALS
cases, suggesting that misfolding and/or altered trafficking of
TDP-43
is relevant to the disease process. Here, we show that the presenilin-binding protein ubiquilin 1 (UBQLN) plays a role in
TDP-43
aggregation.
TDP-43
interacted with UBQLN both in yeast and in vitro, and the carboxyl-terminal ubiquitin-associated domain of UBQLN was both necessary and sufficient for binding to polyubiquitylated forms of
TDP-43
. Overexpression of UBQLN recruited
TDP-43
to detergent-resistant cytoplasmic aggregates that colocalized with the autophagosomal marker, LC3. UBQLN-dependent aggregation required the UBQLN UBA domain, was mediated by non-overlapping regions of
TDP-43
, and was abrogated by a mutation in UBQLN previously linked to Alzheimer disease. Four
ALS
-associated alleles of
TDP-43
also coaggregated with UBQLN, and the extent of aggregation correlated with in vitro UBQLN binding affinity. Our findings suggest that UBQLN is a polyubiquitin-
TDP-43
cochaperone that mediates the autophagosomal delivery and/or proteasome targeting of
TDP-43
aggregates.
...
PMID:Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. 1911 76
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>